Conversion to everolimus in a patient with arterial hypertension and recurrent cutaneous neoplasia - A case report

Nephrology Dialysis Transplantation

Volumn 21, Issue SUPPL. 3, 2006, Pages

  Pascual, Julio ^a   Fernández, Ana M ^a   Marcén, Roberto ^a   Ortuño, Joaquín ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Calcineurin inhibitors; Ciclosporin; Cutaneous neoplasia; Everolimus; Hypertension; Mammalian target of rapamycin inhibitors; Proliferation signal inhibitors

Indexed keywords

ANTILIPEMIC AGENT; ATENOLOL; ATORVASTATIN; CARBAMAZEPINE; CLOPIDOGREL; CREATININE; CYCLOSPORIN A; DOXAZOSIN; EVEROLIMUS; LOSARTAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE;

ADULT; ARTICLE; CASE REPORT; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; EPILEPTIC FOCUS; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; NEPHROTOXICITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE DISEASE; PROTEINURIA; RECURRENT CANCER; SKIN CANCER; SYSTOLIC BLOOD PRESSURE;

BLOOD PRESSURE; CALCINEURIN; CREATININE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE COMPLICATIONS; PREDNISOLONE; SIROLIMUS; SKIN NEOPLASMS; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 33745782733     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl299     Document Type: Article

References (19)

1. European Multicenter Trial Group. Cyclosporin in cadaveric renal transplantation: One-year follow-up of a multicentre trial. Lancet 1983; 2: 986-989
2. Canadian Multicenter Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 1983; 309: 809-815
3. Morales JM, Andres A, Rengel M, Rodicio JL. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant 2001; 16 [Suppl 1]: 121-124
4. Mulay AV, Hussain N, Fergusson D, Knoll GA. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: A systematic review of randomized trials. Am J Transplant 2005; 5: 1748-1756
5. Mulay A, Cockfield S, Fergusson D, Knoll G. Does conversion from a calcineurin inhibitor to sirolimus improve renal function in allograft neuropathy: A systematic review of the evidence. Am J Transplant 2005; 5 [Suppl 11]: A1199
6. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80: 883-889
7. Stallone G, Schena A, Infante B et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352: 1317-1323
8. Chapman JR, Marcen R, Arias M, Raine AE, Dunnill MS, Morris PJ. Hypertension after renal transplantation. A comparison of cyclosporine and conventional immunosuppression. Transplantation 1987; 43: 860-864
9. Bestard O, Cruzado JM, Grinyo JM. Calcineurin-inhibitor-sparing immunosuppressive protocols. Transplant Proc 2005; 37: 3729-3732
10. Pascual J. Concentration-controlled everolimus (Certican ®): combination with reduced dose calcineurin inhibitors. Transplantation 2005; 79: S76-S79
11. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 [Suppl 3]: S112-S119
12. Rigatto C, Parfrey P, Foley R, Negrijn C, Tribula C, Jeffery J. Congestive heart failure in renal transplant recipients: Risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol 2002; 13: 1084-1090
13. Meier-Kriesche HU, Ojo AO, Hanson JA, Kaplan B. Exponentially increased risk of infectious death in older renal transplant recipients. Kidney Int 2001; 59: 1539-1543
14. Meier-Kriesche HU, Ojo AO, Cibrik DM et al. Relationship of recipient age and development of chronic allograft failure. Transplantation 2000; 70: 306-310
15. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: Results from five multicenter studies. Clin Transplant 2004; 18: 446-449
16. Campistol JM, Eris J, Oberbauer R et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk of cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17: 581-589
17. Vìtko S, Margreiter R, Weimar W et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5: 2521-2530
18. Lorber MI, Mulgaonkar S, Butt KMH et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: A 3-year randomized, multicenter, phase III study. Transplantation 2005; 80: 244-252
19. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: A successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004; 77: 760-762